Consultants Responsible for the Program
Prof. Mohamed Mahmoud AbdElhakim
What is neuroblastoma?
Neuroblastoma is a cancer that grows from cells in the nervous system. It forms when healthy nervous system cells do not develop as they should. Instead, cancer cells called "neuroblasts" become stuck in an early stage of development. They do not become healthy, normal cells. The cancer cells begin to grow, and this causes a tumor to form.
Neuroblastoma often starts in the abdomen, either in the adrenal gland or in other nerve cells. It can also form in the neck, chest, or pelvis
Some babies with neuroblastoma do not need treatment. The doctor will follow the tumor's progress closely, and sometimes it will go away on its own.
Some children with neuroblastoma need surgery only.
But about half of neuroblastoma patients have high-risk disease. They need chemotherapy, surgery, radiation therapy, and immunotherapy.
About 700 children are diagnosed with neuroblastoma in the U.S. each year.
Symptoms of neuroblastoma
Signs and symptoms depend on where the cancer is located. They may include:
Other symptoms may include:
Neuroblastoma has often spread to other parts of the body before it is diagnosed.
What is Horner syndrome?
Some neuroblastoma patients develop Horner syndrome, or nerve damage around the eye. Symptoms may include:
Tumor Location |
Symptoms |
Eye |
Bulging eye, dark circles, bruising, blindness |
Neck |
Lump or swelling, Horner syndrome |
Abdomen |
Lump, loss of appetite, vomiting, constipation, pain |
Pelvis |
Change in toilet behavior; bowel or bladder problems |
Spine |
Weakness, paralysis |
Bone |
Pain |
Bone marrow |
Pain, fatigue, burning |
Chest |
Horner syndrome |
Risk factors and causes of neuroblastoma
Neuroblastoma is most common in young children. It happens slightly more often in males than females.
A small number of patients (1–2%) have hereditary neuroblastoma. This can be passed down in families. It is often caused by a change in the ALK or PHOX2B genes. But other gene mutations have also been linked to hereditary neuroblastoma.
Diagnosis of neuroblastoma
Doctors use several types of tests when diagnosing neuroblastoma. Tests may include:
Tumor features and neuroblastoma prognosis
Biology and tumor histology affect neuroblastoma risk and prognosis.
Certain genetic features of the tumor are linked to higher risk. These include:
Stages of neuroblastoma
Neuroblastoma is staged using the International Neuroblastoma Risk Group Staging System (INRGSS). Staging is based on these factors:
Stage |
Spread of disease |
Stage L1 |
The tumor has not spread from where it began. It does not affect important nearby body organs. It is limited to one body area such as the neck, chest, abdomen, or pelvis. |
Stage L2 |
The tumor has not spread to parts of the body that are far away from the tumor. But tests show the tumor is acting more aggressive to nearby areas and organs. These are " image-defined risk factors." The tumor also may have spread nearby. |
Stage M |
The tumor has spread to distant parts of the body. This includes all metastatic disease except Stage MS tumors. |
Stage MS |
For children under 18 months old: Cancer spread is limited to the skin, liver, or less than 10% of bone marrow. |
Neuroblastoma risk groups
Doctors use risk groups to classify neuroblastoma and plan treatments. There are 3 risk groups:
High-risk neuroblastoma means that the cancer is hard to remove and more likely to come back. Children with high-risk neuroblastoma need intense therapy.
Risk groups are based on factors that include:
Treatment of neuroblastoma
Treatment depends on the assigned risk group. Treatment options may include:
Very young, low-risk patients may be followed with observation instead of active treatment. Sometimes neuroblastoma goes away on its own (regression). But this is rare. Patients are watched closely for tumor progression.
Neuroblastoma treatments are planned based on risk groups:
Risk category |
% of new patients |
Main treatments |
Prognosis |
Low Risk |
40% |
Observation |
About 98% survival |
Intermediate Risk |
15% |
Surgery |
About 95% survival |
High Risk |
45–50% |
Surgery |
Less than 60% survival |
Support for neuroblastoma patients
Monitoring for relapse
Patients need follow-up care to watch for recurrence after treatment ends. The medical team will suggest specific tests and their schedule.
In patients who do not have high-risk disease, the chance of relapse is 5–15%. In high-risk patients, the risk of relapse is about 50%. Relapse is most common in the first 2 years after treatment. Relapse is rare when there is no sign of cancer 5 years after completing treatment.
Health after cancer
Survivors treated with chemotherapy or radiation should be monitored for long-term and late effects of therapy. Problems due to treatment could include hearing loss, heart problems, thyroid problems, decreased growth, decreased bone density, and kidney damage.
About 25% of survivors have serious chronic health conditions 25 years after diagnosis
Regular medical checkups by a primary health care provider are important to watch for health problems that can develop years after therapy.
Your child's care team should give you a survivorship care plan after treatment has ended. This report will include needed tests and tips for a healthful lifestyle.
Diagnostics of Neuroblastoma
The program includes:
Required documents
Type of program : Outpatient
Expected duration of the program: 15 days
Chemotherapy of Neuroblastoma
The program includes:
How program is carried out
During the first visit, the doctor will conduct a clinical examination and go through the results of previous laboratory tests and instrumental examinations. After that, you will undergo an additional examination, including laboratory assessment of liver and kidney function, ultrasound scan. Based on the received results, the doctor will elaborate the chemotherapy regimen. If necessary, related medical specialists will be involved in the elaboration of a treatment regimen (tumor board).
Chemotherapy is carried out as the inpatient procedure, with mandatory admission to the hospital. After the placement of a venous catheter, you will stay in a comfortable ward. An infusion system will be connected to the catheter, through which the required drug or a drug combination will be administered. All drugs are administered by intravenous drip, slowly, so the total duration of the infusion can be up to several hours. All this time, doctors and nurses will monitor your health condition closely.
After the course of chemotherapy, you will stay under medical supervision in the ward for a few more hours. After the completion of the chemotherapy course you will receive the medical report with detailed recommendations regarding further treatment. In the future, you will be able to have a distant consultation with your attending physician and schedule the next course of chemotherapy, if necessary.
Required documents
Type of program : Inpatient
Duration: 7 days
Surgical intervention
The program includes:
Required documents
Type of program: Inpatient
Expected duration of the program: 10 days
Radiotherapy
The program includes:
How program is carried out
During the first visit, the doctor will conduct a clinical examination and go through the results of previous laboratory tests and instrumental examinations. After that, you will undergo an additional examination, including complete blood count, laboratory assessment of liver and kidney function. Based on the received results, the physician will conduct radiotherapy planning with the help of CT or MRI, make the permanent tattoo marks on the skin and conduct CT simulation in order to assess the accuracy of the rays and the radiation dose. If necessary, related medical specialists will be involved in the elaboration of a treatment regimen (tumor board).
Radiation therapy is carried out as the day hospital procedure, without mandatory admission to the hospital. At each visit, the physician will assess your general condition and the marks on the skin. After that, you will be placed in a shielded radiation therapy room, on a special table.
Each radiation therapy session lasts less than half an hour (including preparation). All this time, doctors and nurses are monitoring your condition, you can communicate with them through a loudspeaker. The procedure is completely painless. Depending on the planned course of treatment, you will visit the hospital from 1 to 3-5 times a week.
After the completion of the radiation therapy course, you will undergo control examinations aimed at assessing your condition and efficacy of treatment. After that you will receive the medical report with detailed recommendations regarding further follow-up and treatment. In the future, you will be able to have a distant consultation with your attending physician and schedule the next course of treatment, if necessary.
Required documents
Type of program : Outpatient
مؤسسة شفا الأورمان المُشهره بوزارة التضامن الاجتماعي برقم 5859 لسنة 2016
جميع الحقوق محفوظة مستشفي شفاء الأورمان - صعيد بلا سرطان © 2024